Head, Neck and Thyroid Cancers | Key Abstracts in Head, Neck and Thyroid Cancers from the 2022 ASCO Annual Meeting

Featuring an interview with Dr Ezra Cohen, including the following topics:

• Spectrum of targetable mutations in thyroid cancer and impact on treatment selection (0:00)
• Comparative efficacy of TRK inhibitors in patients with thyroid cancer, including those with CNS disease (6:06)
• Current and emerging roles of immunotherapy alone and in combination with tyrosine kinase inhibitors for patients with head and neck cancer (10:17)
• Predicting clinical response to immunotherapy for patients with head and neck cancers (19:47)
• Role of dose reduction in managing toxicities associated with immunotherapy and targeted agents (26:01)
• Current and potential roles for cell-free DNA testing and minimal residual disease assessment in the management of head and neck cancer (32:08)
• Recently reported efficacy data with avasopasem in the treatment of radiation-induced oral mucositis (35:27)
• Factors affecting response to immunotherapy (42:07)

CME information and select publications